Recursion Pharmaceuticals/$RXRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
- Ticker
- $RXRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 600
- Headquarters
- Salt Lake City, United States
- Website
- www.recursion.com
RXRX Metrics
BasicAdvanced
$2.1B
-
-$1.02
1.07
-
Price and volume
Market cap
$2.1B
Beta
1.07
52-week high
$7.18
52-week low
$2.77
Average daily volume
28M
Financial strength
Current ratio
5.034
Quick ratio
4.672
Long term debt to equity
0.048
Total debt to equity
0.073
Interest coverage (TTM)
-371.35%
Profitability
EBITDA (TTM)
-471.604
Gross margin (TTM)
-715.69%
Net profit margin (TTM)
-945.90%
Operating margin (TTM)
-1,002.56%
Effective tax rate (TTM)
0.88%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-27.33%
Return on equity (TTM)
-56.58%
Valuation
Price to revenue (TTM)
32.073
Price to book
2.03
Price to tangible book (TTM)
3.93
Price to free cash flow (TTM)
-4.966
Free cash flow yield (TTM)
-20.14%
Free cash flow per share (TTM)
-0.698
Growth
Revenue change (TTM)
-15.08%
Earnings per share change (TTM)
-43.36%
3-year revenue growth (CAGR)
3.15%
3-year earnings per share growth (CAGR)
-9.39%
What the Analysts think about RXRX
Analyst ratings (Buy, Hold, Sell) for Recursion Pharmaceuticals stock.
Analyst projections of the future price of Recursion Pharmaceuticals stock.
Bulls say / Bears say
Sanofi selected Recursion’s first development candidate from their collaboration, triggering a $10 million payment and moving the programme into Sanofi’s pipeline. Sanofi will fund and lead Phase 1, while Recursion remains eligible for further milestones and double-digit royalties. (GlobeNewswire)
REC-4881 showed a 47% median reduction in gastrointestinal polyp burden after 12 weeks, and 85% of participants remained below baseline after 12 weeks off treatment. If follow-up data support this result and regulators agree a viable trial path, the drug could become a valuable rare-disease treatment. (GlobeNewswire)
Genentech exercised its first validated target option in the neuroscience collaboration, advancing a previously unexplored target into joint small-molecule discovery. This is external validation of Recursion’s discovery work and could lead to further programmes under a collaboration that covers up to 40 potential programmes. (SEC)
Recursion’s clinical record remains mixed: recent BioPharma Dive reporting says disappointing results for REC-994 and a setback with REC-2282 contributed to pipeline cuts. The newer REC-4881 signal is promising, but the platform’s ability to produce successful medicines is not yet established. (BioPharma Dive)
Q2 revenue was only $7.7 million, down from $19.2 million a year earlier, and the company reported $556.8 million in cash at quarter-end. Its SEC filing says substantial losses are expected to continue and significant product revenue is years away, leaving progress dependent on partnerships and access to capital. (SEC)
The $200 million follow-on share offering provides more runway, but issuing new shares dilutes existing owners before Recursion has a commercial product. That makes the financing a cost to shareholders even if it reduces near-term funding risk. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
RXRX Financial Performance
Revenues and expenses
RXRX Earnings Performance
Company profitability
Upcoming events
No upcoming events
RXRX News
AllArticlesVideos
Squeeze Watch: 10 Stocks With Over 33% Short Interest
Benzinga3 weeks ago
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model
Business Wire4 weeks ago
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
MarketBeat4 weeks ago
Funds containing RXRX
AllGBPUSDEUR
Fund name | Fund size | $RXRX weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | £1B | 0.22% |
iShares Ageing Population$AGED | $953M | 0.20% |
iShares Ageing Population€AGED | €822M | 0.20% |
iShares Healthcare Innovation$HEAL | $1.4B | 0.18% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.18% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.